 This study is designed as a phase 1 dose escalation study followed by a randomised phase II study. The study will be performed in three different centres: Addenbrooke Cambridge university Cambridge, UK, Netherlands Cancer Institute Amsterdam, and Vall dHebron Hospital Barcelona, Spain. 